What is a PBM? A plain-English guide for pharmacy owners

Pharmacy Benefit Managers — PBMs — are the most consequential counterparties in the life of an independent pharmacy, and among the least transparent. This guide explains what a PBM actually does, how PBMs make money, the specific contractual relationships that govern your pharmacy's reimbursement, and the audit and compliance mechanics every independent pharmacy owner should understand.

If you have been running a pharmacy for years and feel like you understand PBMs primarily through frustration rather than through structure, this article is designed to fill that gap without condescension.

What a PBM actually does

A Pharmacy Benefit Manager is an intermediary entity that administers prescription drug benefits on behalf of health insurers, employer self-insured plans, Medicare Part D plan sponsors, and government programs. The PBM sits between three groups: the patient's insurance plan, the manufacturer that produces the medication, and the pharmacy that dispenses the prescription.

From the pharmacy's perspective, the PBM does four concrete things. It processes the claim you submit when you fill a prescription. It determines the reimbursement rate under the patient's plan. It deducts any cost-sharing from that reimbursement. And it pays you — typically two to four weeks later — the net amount after any fees, rebates, or adjustments.

From the health plan's perspective, the PBM does something different. It negotiates rebates with manufacturers, designs formularies (the list of drugs covered by the plan), manages utilization through prior authorization and step therapy, and provides clinical management services. The plan pays the PBM a combination of administrative fees and participates in shared savings from the rebates.

The structural issue for independent pharmacies is that the PBM negotiates with both sides simultaneously — pharmacies and plans — and has asymmetric information about what each side is actually paying and receiving.

The largest PBMs and their market position

Three PBMs control the majority of U.S. prescription drug claims volume in 2026. Caremark, owned by CVS Health. Express Scripts, owned by Cigna. And Optum Rx, owned by UnitedHealth Group. Together, these three manage more than 75% of U.S. prescription drug claims.

The remaining PBM market includes Humana Pharmacy Solutions, Prime Therapeutics (owned by a consortium of Blue Cross Blue Shield plans), MedImpact, Navitus, and a range of smaller regional PBMs. Your pharmacy likely has provider agreements with most or all of the major PBMs, because participation is effectively required to access most patient populations.

How PBMs make money

PBM revenue comes from four main sources, and understanding all four is essential to understanding why your contract economics look the way they do.

Administrative fees. Plans pay PBMs flat or per-claim fees to administer prescription benefits. This is the most transparent revenue source and the smallest.

Rebates retained. Manufacturers pay rebates to PBMs in exchange for favorable formulary placement. Plans receive some portion of these rebates, but PBMs typically retain a portion as well. The retained rebate is a primary revenue source and is generally not disclosed to pharmacies.

Spread pricing. On some claims, PBMs charge the plan more for a medication than they reimburse the pharmacy. The difference — the "spread" — is PBM revenue. Spread pricing has been prohibited or constrained in many states and some federal programs, but it remains a meaningful revenue source in others.

DIR fees and performance-based assessments. Retroactive fees charged to pharmacies, some of which may be shared with plans, are a significant revenue category. The mechanics are covered in more detail in our separate article on DIR fees, but the category is substantial.

The provider agreement: what you actually signed

Your relationship with each PBM is governed by a provider agreement and the provider manual that accompanies it. The agreement defines the economic terms and the overall legal framework. The provider manual specifies the operational requirements — documentation, dispensing practices, audit rights, and the specific conditions under which the PBM can recoup payments or terminate your network participation.

Most independent pharmacy owners have signed these agreements years ago without extensive review. The agreements are typically presented as non-negotiable, and the alternative is simply not participating in that PBM's network, which usually isn't economically viable. This means the terms are generally weighted toward the PBM's interests — but understanding the specific terms you signed is the foundation of every audit response, reimbursement dispute, and network participation decision.

If you have not read your current provider manuals recently, the areas most worth reading are audit rights and procedures, documentation requirements, cure period definitions, and termination conditions. Those four sections govern almost all high-stakes interactions with the PBM.

Reimbursement mechanics

When you fill a prescription, the reimbursement you receive is not a simple published rate. It is the result of a multi-step calculation that involves the medication's pricing benchmark, a formula negotiated in your provider agreement, any applicable DIR fees, and the patient's cost-sharing obligation.

The pricing benchmark is usually either the Average Wholesale Price (AWP), the Wholesale Acquisition Cost (WAC), or a Maximum Allowable Cost (MAC) rate set by the PBM. MAC pricing is particularly important because the PBM sets it unilaterally and can update it with limited notice. A pharmacy that acquires a generic medication for $8 may receive reimbursement based on a MAC rate of $7.50, creating a below-cost dispensing event.

The 14 states that require PBMs to disclose MAC methodology and provide an appeal process offer some structural protection. In the other 36 states, below-cost reimbursement on specific medications is a regular operational reality.

Audit rights and what triggers them

Every PBM provider manual includes broad audit rights. The PBM can initiate a desktop audit (document review only), an on-site audit (inspection at your pharmacy), or a combination. Audit selection is typically algorithm-driven — claims patterns that exceed specific thresholds trigger audit selection regardless of any actual concerns about specific dispensing.

The most common triggers include high-cost medication dispensing volume, specific prescriber-pharmacy pair volumes, early refill patterns, adherence outliers, and documentation timestamp inconsistencies. Our article on the most common Optum Rx triggers covers these patterns in more detail.

Network termination

The contractual mechanism that hangs over every PBM dispute is network termination. A PBM that decides to terminate your participation can remove you from its network with notice periods that vary by agreement but are typically 30 to 90 days. Termination from a major PBM can eliminate a substantial percentage of your patient base overnight.

The grounds for termination are broad. Most provider agreements permit termination for material breach (which includes audit findings above certain thresholds), regulatory action, or even "material adverse change" — a broadly worded clause that can apply to many situations the PBM chooses to escalate.

Network terminations from one PBM can also trigger consequences at other PBMs through cross-default clauses, which we cover in our article on network termination cascades.

What to do with this understanding

The practical application of PBM knowledge breaks down into three levels. At the operational level, maintain the documentation discipline that supports clean audit responses and protects against findings. At the contractual level, know what your provider agreements and manuals actually say — including the cure periods, termination conditions, and cross-default clauses that govern disputes. At the strategic level, diversify your PBM network participation to the extent possible, because concentration risk with a single PBM translates directly into business-survival risk if that relationship deteriorates.

None of this eliminates the structural asymmetries of the PBM relationship. But it substantially changes the range of outcomes when a specific issue arises — which is usually the most important variable in pharmacy economics.